Univariate analysis Hazard ratio (95% CI)
p
Age Female sex 0.99 (0.97-1.01) 0.94 (0.56-1.56) 0.19 0.82
Diagnosis MPA GPA 1 1.90 (1.12-3.22)
0.02
Antigenic specificity Anti-MPO Anti-PR3 1 2.34 (1.38-3.97)
0.002
ANCA pattern Monophasic Remitting Persistent Recurrent 1 0.91 (0.26-3.24) 3.36 (1.29-8.79) 4.31 (1.78-10.42) 0.88 0.01 0.001
Clinical features Constitutional symptoms Fever Anemia Microhaematuria Renal failure Alveolar haemorrhage Pulmonary infiltrates Pulmonary nodules Mononeuritis multiplex CNS involvement ENT involvement Purpura Arthritis Ocular involvement 0.65 (0.36-1.16) 0.63 (0.37-1.09) 0.99 (0.40-2.50) 0.73 (0.42-1.29) 0.58 (0.34-0.98) 1.09 (0.62-1.91) 1.66 (0.90-3.06) 1.24 (0.67-2.27) 1.40 (0.68-2.87) 2.83 (0.86-9.29) 2.36 (1.38-4.03) 1.22 (0.57-2.58) 1.82 (1.07-3.12) 2.34 (1,10-4.99) 0.15 0.10 0.99 0.28 0.04 0.78 0.10 0.49 0.36 0.09 0.002 0.61 0.03 0.03
Treatment Cyclophosphamide Azathioprine Methotrexate Mycophenolic acid Plasmapheresis Rituximab 0.68 (0.32-1.42) 1.74 (1.02-2.98) 2.72 (1.38-5.36) 1.41 (0.77-2.60) 0.50 (0.20-1.27) 2.10 (1.20-3.68) 0.30 0.04 0.004 0.27 0.15 0.009